FBR Capital analyst Christopher James weighed in with a few insights on Keryx Biopharmaceuticals (NASDAQ:KERX), after the drug maker announced that the FDA granted approval for …
On October 14th, the American Society of Nephrology (ASN) released the “Kidney Week Abstracts,” including five abstracts from Keryx Biopharmaceuticals’ (NASDAQ:KERX) Aurxyia (ferric …
In a research report released Thursday, FBR Capital analyst Christopher James reiterated an Outperform rating on shares of Anavex Life Sciences Corp. (NASDAQ:AVXL), …
Yesterday morning, Anavex Life Sciences Corp (NASDAQ:AVXL) presented positive data after investigating its pipeline drug Anavex 2073, a sigma-1 receptor antagonist that could …
FBR analyst Christopher James offers insight on shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) after the company reported its third quarter financial results …
Genocea Biosciences Inc (NASDAQ:GNCA) just hosted a conference call to discuss its second-quarter results and to highlight its clinical pipeline progress. The biotech firm continues to commercialize …
In a research report released Tuesday, FBR analyst Christopher James reiterated an Outperform rating on shares of Anavex Life Sciences Corp. (NASDAQ:AVXL), with a $10 price …
After an encouraging update from Keryx Biopharmaceuticals (NASDAQ:KERX) management about approved drug Auryxia, a phosphate binder designed to treat iron deficiency anemia (IDA) …
In a research report released Friday, FBR analyst Christopher James reiterated an Outperform rating on shares of CytRx Corporation (NASDAQ:CYTR), with an $8 price …
